Jean‐Luc Van Laethem

Author

Also Known As

Fernando Rivera, J L Van Laethem, J-L Van Laethem, J. -L. Van Laethem, J. L. VAN LAETHEM, J. L. Van Laethem, J. Van Laethem, J. van Laethem, J.-F Emile, J.-L Van Laethem

423

Publications

16.4K

Citations

H-Index

108

Concepts

All Affiliations

Erasmus Hospital Université Libre de Bruxelles Sorbonne Université Institut Jules Bordet Inserm

About

Jean‐Luc Van Laethem is an author at Erasmus Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	83	7.9K
2	Health Sciences	18	24	1.8K
3	Public Health	2	2	78
4	Language Studies	1	1	21
5	Natural Sciences	1	1	19

Jean‐Luc Van Laethem

141

Publications

14.4K

Citations

H-Index

Page 1

	Year	Citations
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Michel Ducreux, Caroline Caramella, Antoine Hollebecque, Annals of Oncology Surgical OncologyPancreatic CancerGastrointestinal OncologyPancreatic Fluid CollectionMedicine	2015	1.3K
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib Pascal Hammel, F. Huguet, Jean‐Luc Van Laethem, JAMA	2016	1K
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Wendy De Roock, Hubert Piessevaux, Joris De Schutter, Annals of Oncology Gastrointestinal OncologyMedicineMetastatic Colorectal CancerPathologyColorectal Cancer	2007	823
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study Jean-François Bosset, G. Calais, Laurent Mineur, The Lancet Oncology Surgical OncologyFluorouracil-based Adjuvant ChemotherapyEortc 22921Radiation TherapyGastrointestinal Oncology	2014	718
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to <i>BRAF</i> Mutation and Mismatch Repair Status of the MOSAIC Study Thierry André, Armand de Gramont, Déwi Vernerey, Journal of Clinical Oncology	2015	658
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial David Goldstein, Robert H. El-Maraghi, Pascal Hammel, JNCI Journal of the National Cancer Institute	2015	656
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer Eric Van Cutsem, Walter L. Vervenne, Jaafar Bennouna, Journal of Clinical Oncology	2009	642
Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features Francesco Puleo, Rémy Nicolle, Yuna Blum, Gastroenterology Tumor BiologyPancreatic CancerTumor HeterogeneityHistopathologyPathology	2018	553
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Armando Santoro, Lorenza Rimassa, Ivan Borbath, The Lancet Oncology Second-line TreatmentPlacebo-controlled Phase 2OncologyHepatologyMedicine	2012	549
Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy Alain Hendlisz, Marc Van den Eynde, Marc Peeters, Journal of Clinical Oncology	2010	401

Page 1